CPHRF - Cipher Pharmaceuticals Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.8841
0.0000 (0.00%)
At close: 3:45PM EST
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close0.8841
Open0.8841
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.8841 - 0.8841
52 Week Range0.8500 - 1.6600
Volume1,000
Avg. Volume2,687
Market Cap34.98M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.0760
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.77
  • CNW Group

    Cipher Pharmaceuticals Reports Third Quarter 2019 Financial Results

    Cipher Pharmaceuticals Reports Third Quarter 2019 Financial Results

  • Have Insiders Been Buying Cipher Pharmaceuticals Inc. (TSE:CPH) Shares?
    Simply Wall St.

    Have Insiders Been Buying Cipher Pharmaceuticals Inc. (TSE:CPH) Shares?

    It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...

  • CNW Group

    Notice of Cipher Pharmaceuticals Q3 2019 Conference Call

    Notice of Cipher Pharmaceuticals Q3 2019 Conference Call

  • CNW Group

    Cipher Pharmaceuticals Receives Health Canada Approval For Trulance® (Plecanatide)

    OAKVILLE, ON , Oct. 18, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (CPH.TO) ("Cipher" or "the Company") today announced it has received Health Canada approval, on October 10, 2019 , for TRULANCE® (plecanatide), a Guanylate cyclase-C (GCC) agonist in the form of a once-daily tablet for the treatment of adults with irritable bowel syndrome with constipation ("IBS-C"). "We are pleased to announce TRULANCE® has achieved Health Canada approval and we are excited to be able to bring this new and effective treatment option to Canadians who suffer from this condition," said Craig Mull , Interim CEO of Cipher. It is estimated that one in four Canadians has symptoms of constipation and an estimated 38% of Canadians report constipation within the previous 12 months1.

  • What Percentage Of Cipher Pharmaceuticals Inc. (TSE:CPH) Shares Do Insiders Own?
    Simply Wall St.

    What Percentage Of Cipher Pharmaceuticals Inc. (TSE:CPH) Shares Do Insiders Own?

    A look at the shareholders of Cipher Pharmaceuticals Inc. (TSE:CPH) can tell us which group is most powerful. Insiders...

  • CNW Group

    Cipher Pharmaceuticals Reports Second Quarter 2019 Financial Results

    Cipher Pharmaceuticals Reports Second Quarter 2019 Financial Results

  • CNW Group

    Notice of Cipher Pharmaceuticals Q2 2019 Conference Call

    Notice of Cipher Pharmaceuticals Q2 2019 Conference Call

  • CNW Group

    Cipher Pharmaceuticals Announces Management Change & Preliminary Q2 Financial Highlights

    MISSISSAUGA, ON , July 29, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (CPH.TO) ("Cipher" or "the Company") today announced that Mr. Craig Mull has been named Interim Chief Executive Officer of Cipher, replacing Robert Tessarolo . The Company has commenced a formal search process for a new Chief Executive Officer. Mr. Mull is the Chair of the Board of Directors of Cipher and has extensive experience in the Canadian healthcare industry, including holding the position of COO with CML HealthCare, where he was responsible for the day-to-day operations.

  • CNW Group

    Cipher Pharmaceuticals Reports First Quarter 2019 Financial Results

    OAKVILLE, ON , May 10, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (CPH.TO) ("Cipher" or "the Company") today announced its financial and operating results for the three months ended March 31 st, 2019. The Company continues to execute on its corporate strategy focusing on long-term growth. Utilizing cash flows from its profitable global licensing business, Cipher is building a diversified portfolio of prescription products with near term value catalysts.

  • CNW Group

    Notice of Cipher Pharmaceuticals Q1 2019 Conference Call

    Notice of Cipher Pharmaceuticals Q1 2019 Conference Call

  • CNW Group

    Cipher Pharmaceuticals Appoints Mr. Craig Mull to the Board of Directors

    OAKVILLE, ON , March 26, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (CPH.TO) ("Cipher" or "the Company") today announced that Mr. Craig Mull was appointed as a member of the Company's Board of Directors, effective immediately. Mr. Craig Mull is the managing director of 1207407 Ontario Limited and is responsible for overseeing a variety of investments including the company's shareholding in Cipher. Mr. Mull is also the founder and CEO of the Typhon Group Ltd., a privately held real estate development firm which owns and develops commercial and residential projects throughout the Greater Toronto Area .

  • CNW Group

    Cipher Pharmaceuticals Announces Change to Management Team

    OAKVILLE, ON , March 20, 2019 /CNW/ - Cipher Pharmaceuticals Inc. (CPH.TO) ("Cipher" or "the Company") today announced that Stephen Lemieux , Chief Financial Officer and Secretary of Cipher has resigned to pursue other career opportunities. Mr. Lemieux will leave the Company on March 29, 2019 . Mr. Lemieux has agreed to a consulting agreement with the Company to assist in the orderly transition of his responsibilities.

  • CNW Group

    Notice of Cipher Pharmaceuticals Q4 2018 Conference Call

    Notice of Cipher Pharmaceuticals Q4 2018 Conference Call

  • CNW Group

    Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada

    MISSISSAUGA, ON , Dec. 18, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (CPH.TO) today announced that its New Drug Submission ("NDS") for A-101 40% topical solution ("A-101 40%") for the treatment of raised seborrheic keratoses ("SKs") has been accepted for review by Health Canada. Cipher acquired the exclusive Canadian rights to distribute and commercialize A-101 40% from Aclaris Therapeutics, Inc. (ACRS) ("Aclaris") in April 2018 . A-101 40% is a U.S. Food and Drug Administration ("FDA")-approved product indicated for the treatment of raised SKs, which are commonly occurring non-cancerous skin growths that affect more than 9 million Canadian adults and can be an aesthetic skin concern.

  • CNW Group

    Cipher Pharmaceuticals Announces PLECANATIDE Accepted for Review by Health Canada

    MISSISSAUGA, ON , Dec. 17, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (CPH.TO) today  announced that its New Drug Submission ("NDS") for plecanatide for irritable bowel syndrome with constipation ("IBS-C") has been accepted by Health Canada. Cipher acquired the Canadian rights to develop, market, distribute and sell plecanatide (branded as TRULANCE® in the U.S.) from Synergy Pharmaceuticals Inc. (SGYP) ("Synergy") in February 2018 . It is estimated that one in four Canadians has symptoms of constipation and an estimated 38% of Canadians report constipation within the previous 12 months1.

  • CNW Group

    Cipher Pharmaceuticals to Host Investor Webcast on December 11TH, 2018

    MISSISSAUGA, ON , Dec. 5, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (CPH.TO) ("Cipher" or "the Company") today announced that it will host a webcast investor presentation on Tuesday, December 11th at 11:00 AM ET . During the webcast, Robert Tessarolo , President and CEO will provide an introductory presentation through a PowerPoint discussion that will cover key areas of Cipher's business. During parts of the presentation, investors will have an opportunity to ask relevant questions and interact with management through an interactive Q and A portal. An archived version of the webcast and presentation will be available on the Investors section of the Company's website http://www.cipherpharma.com/ following the event.

  • Zacks Small Cap Research

    CORV: Topline Growth Accelerating

    Loss per share was ($0.20) as SG&A expenses grew reflecting an increase in the sales force. Newsflow during the third quarter continued to be very positive for Brinavess, and management has guided to a 2Q:19 resubmission to the FDA. Trevyent is now in the hands of United Therapeutics (UTHR) following their acquisition of SteadyMed.